D
iarrheal illnesses in low-income countries continue to cause substantial morbidity and remain one of the leading causes of death in young children under the age of 5 years in developing countries. Among the bacterial causes of diarrheal illness, enterotoxigenic Escherichia coli strains (ETEC) are commonly linked to more-severe forms of illness in young children (1) . These organisms are perennially the most common cause of diarrhea in those who travel to areas of endemicity where sanitation is poor (2, 3) ; however, they have been identified repeatedly as the etiology of diarrheal outbreaks and sporadic cases of illness in industrialized countries, including the United States (4) (5) (6) (7) (8) .
Acute clinical presentations of ETEC infection may range from mild self-limited illness to severe choleralike diarrhea (9) (10) (11) . In addition, ETEC and other diarrheal pathogens have been linked to pernicious sequelae, including malnutrition, growth stunting, and impaired cognitive development (12) . Presently, there are no vaccines to protect against these common infections. ETEC strains are a genetically (13) and serotypically (14) diverse pathovar of E. coli defined by the production of heat-labile (LT) and/or heat-stable (ST) enterotoxins that activate production of host cyclic nucleotides to alter intestinal salt and water transport that culminate in net fluid losses and secretory diarrhea.
Heat-stable toxins are synthesized as 72-amino-acid proteins consisting of a signal peptide, a propeptide, and a carboxy-terminal region of 18 to 19 amino acids, which forms the mature active enterotoxin (15) . Two enterotoxins cause disease in humans: STp (ST1a), 18 amino acids, and STh (ST1b), 19 amino acids. Both of the mature toxins contain a total of six cysteine residues that form three intramolecular disulfide bonds (16) . Their overall structure is shared with two similar mammalian peptides, guanylin and uroguanylin. Each of the bacterial and mammalian peptides binds to guanylate cyclase C (17, 18) , leading to increases in intracellular cyclic GMP (cGMP) (19) . Increases in cGMP result in activation of protein kinases that phosphorylate and activate the cystic fibrosis transmembrane regulatory (CFTR) channel and inhibit sodium-hydrogen ion exchange via sodium/hydrogen exchanger 3 (NHE3) (20) . These effects lead to a net loss of salt and water into the intestinal lumen with ensuing watery diarrhea.
Bacteria producing any of the toxins LT, STh, or STp have been linked to diarrheal illness in humans (21) (22) (23) (24) , and recent studies suggest that ST-producing ETEC is commonly represented among the pathogens that cause severe diarrheal illness among young children in low-income countries, leading to substantial interest in the development of a vaccine that incorporates ST toxoids (25) .
Enterotoxigenic E. coli strain H10407, originally isolated from a case of severe choleralike diarrheal illness in Bangladesh, is to date the most extensively characterized isolate of this pathovar. Interestingly, this isolate encodes all three canonical enterotoxins associated with ETEC diarrheal illness in humans (26, 27) , with the gene for STh on the largest (94,797-bp) virulence plasmid p948 (NCBI GenBank accession number NC_017724.1) and the genes for both LT and STp on a 66,681-bp plasmid, p666 (NCBI GenBank accession number NC_017722.1) (28) . In addition, H10407 encodes a copy of the ST-like EAST1 peptide (29) on the large p948 plasmid (30) . H10407 is frequently used as the challenge strain in controlled human infection models to test candidate vaccines. Therefore, we set out to examine the relative contribution of STh and STp to the accumulation of cGMP in host epithelia by H10407 and the ability of anti-ST and antiadhesin antibodies to mitigate effective toxin delivery by the bacteria.
RESULTS
Contributions of STh, STp, and EAST1 to activation of cGMP in target epithelial cells. Understanding the individual contributions of ST and ST-like molecules of ETEC is relevant to development and testing of toxin neutralization strategies. H10407 encodes three peptides with the potential to activate cGMP in target intestinal epithelial cells: STh, STp, and EAST1, a heat-stable toxin originally identified in enteroaggregative E. coli (29) . STh is encoded by the estH gene on the large, 94,797-bp plasmid p948 (NCBI GenBank accession NC_017724.1). The astA gene, which encodes the EAST1 peptide (30) , is embedded within an IS1414 insertion sequence (31) and is also located on the p948 plasmid immediately downstream from the etpBAC adhesin locus (28, 32) . STp is encoded by the estP gene on a second, 66-kb virulence plasmid (NCBI GenBank accession number FN649417.1) in H10407.
We found that deletion of estH resulted in appreciable decreases in cGMP production at or near background levels of cGMP production by uninfected cells and that complementation of estH in trans restored activation of this cyclic nucleotide (Fig. 1A) . In contrast, the estP mutant was not appreciably different from the wild-type strain, and the introduction of the estP mutation to the estH strain did not yield further measurable decreases in cGMP production by target epithelial cells. Similar results were obtained at various multiplicities of infection (MOIs) (Fig. 1B) , suggesting that this was not related to a spurious inoculum effect. In addition, infection of small intestinal enteroids demonstrated that while deletion of estH alone resulted in a substantial decrease in the production of cGMP in target epithelia to background levels, deletion of estP had no demonstrable effect on cyclic nucleotide production (Fig. 1C) . However, we found that in distinct contrast to an A14Q mutant STh peptide (25) , the target T84 cells did respond to glutathione S transferase (GST) fusions to either STh or STp (Fig. 1D) and that estP complementation of the estH estP dual deletion mutant in trans was sufficient to completely restore activation of cGMP to wild-type levels (Fig. 1E) , clearly suggesting that enterocytes have the capacity to respond to either peptide. These results suggested that deletion of estP results in a compensatory increase in estH transcription and/or secretion of the encoded peptide. Interestingly, we found that relative to what was seen in the wild-type strain, estH transcription was significantly increased in the estP mutant (Fig. 1F) , while transcription of estP in the estH mutant was not substantially increased (Fig. 1G) . Collectively, these results suggest that both ST peptides likely act in conjunction with heat-labile toxin to cause the diarrheal illness associated with the H10407 strain, but the molecular details governing transcriptional regulation of toxin production have not been completely elucidated. Because we previously demonstrated that a number of virulence factors are transcriptionally modulated by ETEC pathogen-host cell interaction (33) we also examined transcription of both ST toxin genes and tolC, which encodes the putative export channel for ST. Interestingly, we found that in contrast to estH, estP transcription was significantly influenced by bacterial cell contact, with transcription of the gene encoding STp enhanced by bacterial adhesion, as was the tolC gene (Fig. 1H ). These data suggest that similar to LT, the secretion and delivery of one or both of the STh and STp heat-stable toxins are likely highly orchestrated by contact with the intestinal epithelia.
In addition to STh and STp, earlier studies demonstrated that ETEC strains, including H10407 (31), also encode EAST, a heat-stable toxin originally identified in enteroaggregative E. coli (29, 31) . Although the structures of the mature EAST and STh peptides are similar, there is only 37% identity (7/19 amino acids) between the two molecules (29), a finding that could impact the rational design of toxoids if EAST contributes to ETEC diarrheal illness. However, induction of cGMP in monolayers infected with a strain carrying an isogenic mutation of the astA gene, encoding EAST on the large p948 virulence plasmid of H10407 (3.8 Ϯ 0.42 pmol/ml), was not significantly different from that of the wild-type parent (4.0 Ϯ 0.35 pmol/ml), while deletion of both estP and estH resulted in complete abrogation of cGMP production (0.52 Ϯ 0.06 pmol/ml), findings that suggest that EAST may not contribute significantly to diarrheal illness caused by this particular ETEC isolate.
TolC is required for effective ETEC secretion of STh and STp. The precise mechanism for secretion of heat-stable toxins from ETEC strains associated with disease in humans is presently uncertain. Prior studies of heat-stable toxin investigated the secretion of STb (ST-II) (34) or STp (STIa) (35) from laboratory strains of E. coli containing recombinant expression plasmids. While both studies suggested that the outer membrane protein TolC is involved in secreting these toxins from the recombinant E. coli background, there are conflicting data regarding the involvement of the STb (STII) toxin in human disease (36, 37) , and unlike the STh and STp toxins, STb does not bind to guanylate cyclase C. Similarly, to our knowledge, there has been no verification of the role of tolC in mediating the secretion of either of the ST1 toxins (STh and STp) from strains of ETEC isolated from humans. Therefore, to verify the importance of TolC in secretion of both STh and STp from ETEC strains that cause human illness, we constructed an isogenic tolC mutant in the ETEC H10407 strain and tested the ability of the mutant bacteria to deliver ST to target epithelial cells.
We found that mutants lacking tolC were devoid of detectable toxin in culture supernatants ( Fig. 2A ) and were markedly deficient in their ability to deliver ST toxins to epithelial monolayers, as we observed only background levels of cGMP production following infection with the tolC mutant strain, and complementation with tolC in trans restored the ability of the bacteria to provoke a cGMP response in targeted cells (Fig. 2B) .
Optimal delivery of ST requires the EtpA adhesin. We have previously demonstrated that intimate interaction of ETEC with intestinal epithelial cells is essential for efficient delivery of heat-labile toxin to intestinal epithelial cells (38) . Moreover, delivery of LT requires the concerted action of several ETEC adhesins with different receptor specificities (39, 40, 52) including EtpA, a plasmid-encoded secreted adhesin (32) that serves as a molecular bridge between bacteria and intestinal epithelial cells (42) . EtpA is expressed by a diverse population of ETEC isolates (43) , is recognized during the course of infection (44), and is a protective antigen in preclinical models of ETEC infection (40, 45, 46) .
Because we are exploring the role of EtpA as a protective immunogen (47) and ST-producing ETEC strains have predominated in recent epidemiologic studies (1, 48), we set out to examine the dependence of ST delivery on EtpA-mediated bacterial adhesion by comparing cGMP activation of target intestinal epithelial cells infected with wild-type ETEC to that in cells infected with an isogenic etpA mutant. These studies demonstrated that cGMP activation in target epithelia by wild-type bacteria was significantly accelerated relative to that seen with the etpA mutant ( Fig. 3) , suggesting that efficient delivery of these small peptides also requires effective bacterium-host interactions.
Similarly, we found that antibodies directed against either the EtpA adhesin molecule or STh significantly inhibited the delivery of heat-stable toxins to target cells (Fig.  4 ). Although we were not able to demonstrate that the combination of these antibodies was synergistic, these data provide additional support to the concept that EtpA could be useful as a target to engender coverage against a wide variety of ETEC isolates that produce heat-stable and/or heat-labile enterotoxins (43, 49) .
Delivery and secretion of epitope-tagged STh. Understanding the nature of ST secretion and its delivery to epithelial receptors could be relevant to an informed development of ST toxoid molecules. STh is synthesized as a 72-amino-acid molecule that includes a 19-amino-acid signal peptide, followed by a 34-amino-acid propeptide and a mature ST molecule of 19 amino acids. Although most attempts to develop ST toxoids have targeted the mature peptides (16, 25) , there are earlier but conflicting data regarding the precise form of ST that is secreted into the extracellular milieu (15, 50) , with some data suggesting that the propeptide may be exported with subsequent processing to the mature peptide outside the bacteria (51). To investigate the potential secretion of the propeptide, we engineered 3ϫFLAG-epitope fusions to the amino- terminal end of the propeptide region (FLAG 3 -pro-STh) of STh and compared the export and delivery of the resulting peptides to those of carboxy-terminal fusions to the mature peptide (pro-STh-FLAG 3 ) (Fig. 5 ).
B S A w t t o l C e s t H e s t P G S T -S
We were able to recover either the amino-terminal or carboxy-terminal FLAG-tagged molecules from culture supernatants of estH estP mutant ETEC transformed with the pSTh-FLAG 3 or pFLAG 3 -STh plasmids, respectively (Fig. 5a ). Both molecules appeared to yield functional ST mature peptides, as either plasmid was sufficient to complement the ability of the estH estP mutant to activate cGMP in target epithelial cells (Fig. 5b) . Likewise, we were able to demonstrate binding of FLAG-epitope-tagged molecules to target epithelial cells following infection with either of the complemented strains ( Fig.  5c and d) . Collectively, these data appear to reaffirm earlier observations of STh (51), suggesting that both the mature form (19 amino acids) of the peptide and the extended pro-STh (53 amino acids) may be found outside the bacteria.
DISCUSSION
Because of the significant global burden of diarrheal illness caused by ETEC, these pathogens have been a target for vaccine development since they were first identified as a cause of severe diarrheal illness more than 4 decades ago. Currently, there is no vaccine available that affords broad-based protection against ETEC, in part due to the substantial antigenic diversity within the pathovar and limited mechanistic insight into immunologic correlates of the protection that appears to follow early infections among young children in areas of endemicity. Moreover, many features of the molecular pathogenesis of these common pathogens have not been explored in sufficient detail to inform vaccine development. Because ST-producing ETEC isolates comprise a large proportion of strains associated with symptomatic diarrheal illness (1), we investigated the molecular contributions of the known heat-stable toxins, their proposed secretion apparatus, and bacterial adhesion to toxin delivery. The present studies suggest that efficient delivery of ST toxins is a complex process that requires the ability to effectively engage host cells and produce at least transient adhesion afforded by EtpA and other adhesins (52) . Moreover, as antibodies directed at either the EtpA adhesin or ST impaired toxin delivery, our studies provide further support for development of a vaccine platform that combines ST toxoid (25) and antiadhesin approaches. However, further studies will be needed to define an optimal vaccination approach capable of generating sufficient antibodies to neutralize binding of the small ST peptides to cognate receptors in the small intestine.
Our data provide an important validation of the potential biologic importance of both STh and STp toxins. While recent large-scale epidemiologic data have highlighted the importance of ETEC strains producing STh as a cause of moderate to severe diarrhea in young children (1), subsequent reevaluation of these data has suggested that STp-producing strains also contribute significantly to the overall burden of illness DAPI αO78 αFLAG αFLAG αO78 DAPI merge associated with ETEC (48). Indeed, earlier clinical studies demonstrated that while there were regional differences in the distribution of STp and STh among ETEC isolates, both peptides were commonly associated with diarrheal illness, and the clinical presentations attributed to ETEC producing either ST peptide were indistinguishable (24) . In keeping with these observations, we found no difference in the ability of STh or STp peptides to elicit cGMP production (19) in target epithelia. Although deletion of the gene encoding STh resulted in lower cGMP production in infected monolayers than when the estP gene was deleted from the ETEC H10407 strain, we discovered a compensatory increase in transcription of estH in the estP mutant. Collectively, therefore, our results suggest that both peptides likely contribute to diarrheal illness caused by H10407. Indeed, deletion of the tolC gene, which encodes the membrane transporter for both peptides, resulted in complete abrogation of cGMP activation in target epithelial cells, similar to deletion of both the estH and estP toxin genes from H10407.
Earlier studies also noted that many ETEC strains, including H10407, bear copies of an insertion sequence (31) that encompasses the astA gene encoding EAST1 (30), a cGMP-activating peptide structurally similar to ST1 that was originally identified as a heat-stable enterotoxin in enteroaggregative E. coli (29) . However, we saw similar increases in cGMP production by target epithelial cells following infection with the astA mutant and wild-type ETEC. We cannot rule out the possibility of EAST1 expression from additional copies of astA not residing on the large, p948 virulence plasmid or that EAST1 is not optimally expressed in vitro. However, the complete absence of a cGMP response in cells infected with the STh/STp deletion mutant might alternatively suggest that EAST1 does not contribute to ETEC virulence and that further toxoid vaccine development can simply focus on engendering neutralizing antibody responses to the established ST and LT enterotoxins.
The reaffirmation of TolC as a key mechanism for export of ST1 toxins could be relevant to the management of diarrheal illness. The rapid emergence of multidrug resistance in the Enterobacteriaceae that is in part dependent on drug efflux through TolC has stimulated interest in efflux inhibitors to enhance the potency of available antimicrobial agents (53) (54) (55) . Theoretically, these inhibitors could offer novel therapeutic agents for treatment of ETEC.
Our studies also revisit the concept that the larger propeptide form of STh may be exported by the bacteria, and the data presented here are consistent with prior observations suggesting that some processing of the propeptide occurs outside the bacteria (15, 51) . Further study will be needed, however, to determine whether the propeptide sequence contributes to immunologic recognition of ST following infection and whether these larger molecules might be exploited in the development of improved toxoids to neutralize ST.
MATERIALS AND METHODS
Bacterial strains and growth conditions. Bacterial strains used are listed in Table 1 . For general purposes, ETEC bacteria were grown in lysogeny broth at 37°C overnight from frozen glycerol stocks. To optimize synthesis and secretion of ST toxin, bacteria were grown in Casamino Acids-yeast extractsucrose medium (CAYE-ST) (2% Casamino Acids, 0.6% yeast extract, 43 mM NaCl, 38 mM K 2 HPO 4 , 203 mM MgSO 4 , 25 mM MnCl 2 , 18 mM FeCl 3 , 2% sucrose) at 37°C overnight from frozen glycerol stocks.
Construction of mutants lacking production and secretion of heat-stable toxins. Lambda red recombinase-mediated recombination (56) was used to disrupt genes encoding heat-stable toxins in H10407. In brief, we used the primers jf070212.1 and jf070212.2 to amplify the kanamycin (Km) cassette from pKD13 with a 36-bp overhang sequence from the estH gene and primers jf070212.3 and jf070212.4 to amplify the kanamycin cassette from pKD13 with a 36-bp overhang sequence from the estP gene. The PCR product was electroporated into competent H10407 containing helper plasmid pKD46 and selected on LB plates with 50 g/ml kanamycin. Kanamycin-resistant (Km r ) colonies were screened by PCR with primers jf071612.1 and jf071612.2 for the estH locus and with primers jf071612.3 and k2 for estP. The deletion mutants were further confirmed by toxin multiplex PCR as previously described (57) .
To construct complemented strains, we amplified the estP gene with primers jf030316.3 and jf060614.1 for cloning into the XhoI site of pBAD/mycHisA, yielding pQL239; estH was amplified with primers jf072414.5 and jf072414.6 and cloned into the EcoRV site of pACYC184 to produce pSMD001. We also cloned estH and estP genes individually and together in pETDuet-1 at NcoI and EcoRI sites and at BglII and XhoI sites with primer pairs jf060614.2/jf060614.3 and jf060614.4/jf060614.5, respectively. This resulted in plasmids pQL230 (estP), pQL231(estH), and pQL238 (estP estH) ( Table 1) . After confirmation by sequencing, the respective plasmids were transformed into the deletion strains, and complementation was confirmed by PCR.
To generate an ETEC tolC deletion mutant, primers jf110716.44/45 were first used to amplify a ΔtolC732::Km r fragment from JQ55031 (58) . Next, the regions flanking tolC in the H10407 genome were amplified with primer pairs jf110716.38/jf110716.43 and jf110716.46/jf110716.39 to amplify 1,027 bp of upstream sequence and 985 bp of downstream sequence, respectively. The three resulting fragments were then fused by PCR with primer pairs jf110716.38/jf110716.39, using high-fidelity polymerase Phusion (Thermo Fisher Scientific), with denaturing for 2 min at 98°C, followed by 30 cycles of 10 s at 98°C, 30 s at 65°C, and 1.5 min at 72°C and a final extension for 10 min at 72°C. The resulting 3,325-bp amplicon was then introduced into H10407(pKD46) as described above. Kanamycin-resistant, ampicillinsensitive colonies were then screened by colony PCR using primer pair jf112016.50/51 flanking the entire amplicon for a 4,269-bp product and primers jf101716.21/22 specific to tolC gene (603-bp product). Primers k2/jf112016.51 (2,024-bp product) were then used to confirm the tolC gene deletion and the Km r cassette integration in the H10407 genome. To complement the tolC mutant, the tolC gene was amplified from H10407 genomic DNA using primers jf120716.59/jf120716.60, and the plasmid vector backbone was amplified from plasmid pBAD/myc-His B using primers jf120716.52/jf120716.53. The recombinant pYZ008 complementation plasmid was assembled using an adaptation of circular polymerase extension cloning (CPEC) (59) (30 s of denaturation at 98°C, followed by 20 cycles of 10 s at 98°C, 30 s at 55°C, and 1.5 min at 72°C and a final extension for 10 min at 72°C). Following sequence verification, pYZ008 or the pBAD/myc-His B vector control plasmids were then used to transform the ΔtolC mutant. Complementation was confirmed by PCR with primers jf101716.21/22. FLAG-STh fusions. FLAG epitope fusions were constructed to introduce the 3ϫFLAG sequence between the signal peptide of estH and the beginning of the propeptide-encoding region (on plasmid pFLAG 3 -STh) or at the 3= end of estH (on pSTh-FLAG 3 ). The 3ϫFLAG fragment was first constructed by annealing complementary synthetic oligonucleotides jf092616.9 encoding positive-strand bases 1 to 43 and jf092616.10 representing negative-strand bases 66 to 19 of a 66-bp sequence encoding the 3ϫFLAG peptide (DYKDHDGDYKDHDIDYKDDDDK).
To generate plasmid pFLAG 3 -STh, in which the 3ϫFLAG-encoding sequence was inserted between the STh signal peptide and the STh propeptide, primers jf101916.33/jf092616.4 were first used to amplify the nucleotides (1 to 63) of estH encoding the signal peptide. Next, primers jf092616.1/jf092616.2 were used to amplify the 3ϫFLAG fragment from the above-described synthetic oligonucleotide 3ϫFLAG template flanked by nucleotide extensions representing nucleotides 44 to 60 and 64 to 99 of estH, while primers jf092616.3/jf101916.34 were used to amplify the 3= end of estH from nucleotide 64 to the native stop codon. The three fragments were fused in a single PCR using primers jf101916.33/jf101916.34. Next, the vector backbone was amplified using primers jf101916.31/jf101916.32 from pFLAG-CTC (Sigma), followed by the final assembly of pFLAG 3 -STh by CPEC. Similarly, to make plasmid pSTh-FLAG 3 , primers jf092616.5/jf101916.35 were used to amplify 3ϫFLAG with a 5= nucleotide extension representing nucleotides 197 to 216 of estH, while primers jf101916.33/jf092616.8 were used to amplify the estH gene with a 5= nucleotide extension corresponding to pFLAG-CTC. The resulting amplicons were then fused in a single PCR using primers jf101916.33/jf101916.35 and assembled with the pFLAG-CTC backbone by CPEC.
Cloning, expression, and purification of recombinant ST proteins peptides. To construct a GST-STh or mutant GST-mSTh (A14Q) expression plasmid, synthetic oligonucleotides that encompassed the region of the estH gene corresponding to the mature peptide minus the native start codon, preceded by an in-frame flexible linker sequence (60), were synthesized (IDT, Coralville, IA). The forward sequence (jf042715.1 for STh and jf042517.1 for mSTh), preceded by a BamHI overhang sequence (GATCC), and the reverse sequence (jf042715.2 for STh and jf042517.2 for mSTh), preceded by an EcoRI overhang sequence (AATTC), were mixed in a 1:1 molar ratio, heated to 95°C for 5 min, and cooled to room temperature. The annealed double-stranded 91-bp DNA fragments were then cloned directly into the pGEX-4T1 vector digested with BamHI and EcoRI, yielding plasmids pCW002 and pYZ011, respectively. A similar strategy was to construct a GST-STp expression plasmid using forward oligonucleotide jf031915.5 and the reverse sequence jf031915.6, resulting in plasmid pCW003. E. coli TOP10(pCW002), TOP10(pCW003), and TOP10(pYZ011) were then used to express recombinant GST-STh, GST-STp, and GST-mSTh, and the resulting fusion proteins were purified by affinity chromatography. In brief, the bacterial cultures were grown in Luria broth at 37°C to an optical density at 600 nm (OD 600 ) between 0.6 and 0.7 and induced with 1 mM (final concentration) IPTG (isopropyl-␤-D-thiogalactopyranoside) for 1 to 3 h. The cell pellets were resuspended in 30 ml cold phosphate-buffered saline (PBS) containing 5 mM dithiothreitol (DTT), 1 protease inhibitor tablet (Roche), and 0.1 mg/ml lysozyme. Following sonication, supernatants were clarified by centrifugation at 12,000 rpm for 20 min at 4°C, followed by passage through a 0.45-m filter. Filtered supernatants were then loaded onto columns (glutathione Sepharose High Performance; GE Healthcare) preequilibrated with PBS, pH 7.3 (140 mM NaCl, 2.7 mM KCl,10 mM Na 2 HPO 4 , 1.8 mM KH 2 PO 4 [pH 7.3]). After washing with 20 column volumes of PBS containing 1 mM DTT, GST fusion proteins were eluted in fresh buffer containing 100 mM Tris-HCl (pH 8.0) and 10 mM reduced glutathione and dialyzed against PBS.
To liberate native STh or mutant STh (mSTh) from its GST fusion partner, GST-fusion protein was dialyzed in 50 mM NH 4 HCO 3 (pH 8.5) containing 1 unit of thrombin (Sigma) per mg GST-fusion protein at 4°C overnight, centrifuged at 4,000 ϫ g for 20 min with a 10-kDa-molecular-weight cutoff (MWCO) centrifugal filter to collect the filtrate, and dried by vacuum centrifugation. Peptide concentrations were then determined by measurement of the molar extinction coefficient at 280 nm (Take3; BioTek).
Transcriptional analysis of estH, estP, and tolC genes. To assess transcription of toxin genes in mutant strains relative to wild-type H10407, the bacteria were grown overnight in 2-ml cultures of lysogeny broth at 37°C and 225 rpm and then diluted 1:100 into fresh medium and grown for an additional 3 h. To assess modulation of transcription upon cell contact, confluent T84 cells were inflected with early-log-phase H10407 bacteria (ϳ10 9 CFU) for 30 or 90 min. Total RNA was isolated from adherent and planktonic (nonadherent) bacterial fractions using an RNAspin Mini isolation kit (25050070; GE Life Sciences) and treated with DNase I (18068015; Thermo Fisher). PCR for the arcA housekeeping gene was used to confirm the removal of DNA. Total RNA was reverse transcribed (SuperScript VILO cDNA synthesis kit, 11754250; Thermo Fisher). RNA transcripts were quantified by real-time (RT) PCR (Fast SYBR green master mix, number 4385612 from Thermo Fisher; ViiA 7 real-time PCR system from Applied Biosystems). Primers specific to the arcA, estH, estP, and tolC genes are listed in Table 2 . All transcripts were normalized to arcA and are presented as a ratio of transcripts in adherent bacteria relative to transcripts in planktonic bacteria.
Production and purification of anti-ST polyclonal antibody. To generate rabbit polyclonal antibody that recognizes STh, New Zealand White rabbits were immunized (Rockland) with recombinant GST-STh. We used lyophilized E. coli AAEC191A (61) and an immobilized E. coli lysate column (44938; Pierce) to adsorb E. coli-reactive antibodies, followed by protein G column purification (HiTrap, GE17-0404-01). IgG GST-STh antibodies were affinity purified using GST-STh immobilized on nitrocellulose as previously described, and anti-GST-reactive antibodies were removed by cross-adsorption against GST coupled to glutathione agarose resin (G-250-100; Gold Biotechnology, St. Louis, MO). 
Confocal immunofluorescence imaging and quantification.
To examine the delivery of FLAGtagged STh toxin to intestinal epithelial cells, estP estH mutant strains with or without plasmids encoding FLAG-tagged STh were grown overnight and diluted 1:50 in CAYE-ST medium, grown to an OD 600 of ϳ0.2, and then induced with 1 mM IPTG for 2 h. The bacteria were added to T84 cells at a multiplicity of infection (MOI) of ϳ1:50, maintaining the induction with 1 mM IPTG. After infection with the bacteria, T84 cells were washed with PBS, fixed with 4% paraformaldehyde for 10 min at room temperature, permeabilized with 0.1% Triton X-100 for 5 min, and blocked with 1.5% bovine serum albumin (BSA)-PBS at 37°C for 1 h. Anti-O78 rabbit polyclonal antiserum (Penn State University) diluted 1:300 in PBS with 0.02% Tween 20 (PBST) and 1.5% BSA was used to identify H10407 and monoclonal anti-FLAG M2 antibody (number F1804; Sigma) diluted 1:500 in PBST with 1.5% BSA to detect FLAG-tagged STh. Following incubation overnight at 4°C, slides were washed 3 times with PBS and incubated for 1 h at 37°C with goat-anti-rabbit IgG (H&L) Alexa Fluor 488 conjugate (A11070; Thermo Fisher) and goat-anti-mouse IgG (H&L) conjugated to Alexa Fluor 594 (A11032; Thermo Fisher) at a dilution of 1:500 in PBST containing 1.5% BSA. After washing, DAPI (4=,6-diamidino-2-phenylindole) was added at 1:6,000. Confocal microscopy images were acquired using a Nikon C2ϩ confocal microscope system. To quantitate binding of FLAG-epitope-tagged STh molecules, fluorescence detection was normalized to the DAPI signal using NIS-Elements DUO software (v4.4).
In vitro assessment of toxin delivery. Cultures of bacteria were grown overnight in lysogeny broth from frozen glycerol stocks in CAYE-ST medium. Phosphodiesterase inhibitors (PDE-I) vardenafil hydrochloride trihydrate (number Y0001647), rolipram (number R6520), and cilostazol (number C0737) (all from Sigma-Aldrich) were each added to target intestinal epithelial cells at a final concentration of 16.7 or 50 M and incubated with cells for 1.5 h (T84 cells) or 2 h (enteroids). Bacteria or toxin was added to T84 monolayers seeded into 96-well plates, and the treatment was continued for the indicated duration. After washing in PBS, cyclic GMP (cGMP) levels were determined by enzyme immunoassay (EIA; K020-H1; Arbor Assays) using the acetylated protocol as directed by the manufacturer.
To examine the capacity of antibodies to neutralize ST delivery, antibody against STh and/or EtpA was added directly to T84 cell monolayers at the indicated dilution at the time of infection. After 1.5 h, cells were washed by PBS and lysed, and cGMP assays were performed as described above.
Growth and differentiation of T84 cells and small intestinal enteroids. T84 intestinal epithelial cells (ATCC CCL-248) were cultured in 96-well plates for 24 to 48 h at 37°C, 5% CO 2 incubator, to Ͼ90% confluence in a 1:1 mixture of Dulbecco's modified Eagle medium (DMEM)/F12 medium supplemented with L-glutamine (2.5 mM) and fetal bovine serum (FBS; 5% [vol/vol] ). Enteroids were grown as previously described in detail (62, 63) . Briefly, cells obtained from the Washington University Digestive Diseases Research Core Center BioSpecimens Core were propagated in Matrigel (BD Biosciences, San Jose, CA) in 24-well plates at 37°C with a 1:1 mixture of L-WRN (Wnt3a, R-spondin, and Noggin) conditioned medium (CM) and primary culture medium (Advanced DEM/F12; Invitrogen) supplemented with 20% FBS, 2 mM L-glutamine, 100 units/ml penicillin, 0.1 mg/ml streptomycin, 10 M Y-27632 (ROCK inhibitor; Tocris Bioscience, R and D Systems, Minneapolis, MN), and 10 M SB 431542 (TGFBR1 inhibitor; Tocris Bioscience, R and D Systems). Cells were then added to Transwell filters (Corning) and incubated in differentiation medium (1:20 mixture of L-WRN CM and primary culture medium) lacking SB 431542 and were grown 2 to 3 days until confluence. Prior to addition of bacteria, cells were switched to differentiation medium lacking antibiotics. Accession number(s). Plasmids pCW002, pCW003, and pYZ011 have been deposited in Addgene (https://www.addgene.org/) under accession numbers 90225, 90226, and 110570, respectively.
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